Table 1 Comparison of clinicopathologic characteristics and molecular subtypes among estrogen receptor-positive breast cancers stratified into epithelial, intermediate, and mesenchymal phenotypes within the TCGA-BRCA cohort
Cases | Â | Total (803) | Epithelial (268) | Intermediate (267) | Mesenchymal (268) | P-value |
|---|---|---|---|---|---|---|
Age (years) | Mean ± SD | 59 ± 13 | 61 ± 14 | 59 ± 13 | 57 ± 13 | 0.002 |
Menopausal status | Pre | 163 (20.3%) | 44 (16.4%) | 62 (23.2%) | 57 (21.3%) | 0.095 |
Post | 526 (65.5%) | 191 (71.3%) | 170 (63.7%) | 165 (61.6%) | Â | |
Others | 114 (14.2%) | 33 (12.3%) | 35 (13.1%) | 46 (17.1%) | Â | |
Histological type | Ductal | 538 (67.0%) | 192 (71.6%) | 183 (68.5%) | 163 (60.8%) | < 0.001 |
Lobular | 190 (23.7%) | 39 (14.6%) | 68 (25.5%) | 83 (31.0%) | Â | |
Others* | 75 (9.3%) | 37 (13.8%) | 16 (6%) | 22 (8.2%) | Â | |
Clinical T stage | T1 | 212 (26.4%) | 57 (21.3%) | 72 (27%) | 83 (31.0%) | 0.124 |
T2 | 452 (56.3%) | 154 (57.5%) | 156 (58.4%) | 142 (53.0%) | Â | |
T3 | 111 (13.8%) | 44 (16.4%) | 33 (12.4%) | 34 (12.7%) | Â | |
T4 | 26 (3.2%) | 11 (4.1%) | 6 (2.2%) | 9 (3.3%) | Â | |
unknown | 2 (0.2%) | 2 (0.7%) | 0 (0%) | 0 (0%) | Â | |
Clinical N stage | N0 | 354 (44.1%) | 120 (44.8%) | 112 (41.9%) | 122 (45.5%) | 0.784 |
N1 | 284 (35.4%) | 96 (35.8%) | 96 (36%) | 92 (34.3%) | Â | |
N2 | 90 (11.2%) | 27 (10.1%) | 30 (11.2%) | 33 (12.3%) | Â | |
N3 | 59 (7.3%) | 18 (6.7%) | 22 (8.2%) | 19 (7.1%) | Â | |
unknown | 16 (2.0%) | 7 (2.6%) | 7 (2.6%) | 2 (0.8%) | Â | |
Clinical M stage | M0 | 651 (81.1%) | 222 (82.8%) | 212 (79.4%) | 217 (81.0%) | 0.429 |
M1 | 16 (2.0%) | 2 (0.8%) | 8 (3%) | 6 (2.2%) | Â | |
unknown | 136 (16.9%) | 44 (16.4%) | 47 (17.6%) | 45 (16.8%) | Â | |
Clinical stage | I | 140 (17.4%) | 41 (15.3%) | 50 (18.7%) | 49 (18.3%) | 0.333 |
II | 442 (55%) | 157 (58.6%) | 139 (52.1%) | 146 (54.5%) | Â | |
III | 190 (23.7%) | 64 (23.9%) | 66 (24.7%) | 60 (22.4%) | Â | |
IV | 15 (1.9%) | 1 (0.4%) | 8 (3%) | 6 (2.2%) | Â | |
unknown | 16 (2.0%) | 5 (1.8%) | 4 (1.5%) | 7(2.6%) | Â | |
ER level (%) | ≥ 90 | 191 (23.8%) | 71 (26.5%) | 71 (26.6%) | 49 (18.3%) | 0.020 |
≥ 50 and<90 | 83 (10.3%) | 16 (6.0%) | 28 (10.5%) | 39 (14.6%) |  | |
≥ 10 and<50 | 42 (5.2%) | 13 (4.9%) | 10 (3.7%) | 19 (7.1%) |  | |
<10 | 16 (2.0%) | 5 (1.9%) | 5 (1.9%) | 6 (2.2%) | Â | |
unknown | 471 (58.7%) | 163 (60.8%) | 153 (57.3%) | 155 (57.8%) | Â | |
PR expression | Positive | 604 (75.2%) | 189 (70.5%) | 211 (79%) | 204 (76.1%) | 0.191 |
Negative | 112 (13.9%) | 42 (15.7%) | 34 (12.7%) | 36 (13.4%) | Â | |
unknown | 87 (10.8%) | 37 (13.8%) | 22 (8.2%) | 28 (10.4%) | Â | |
HER2 status | Positive | 141 (17.6%) | 36 (13.4%) | 49 (18.4%) | 56 (20.9%) | 0.073 |
Negative | 507 (63.1%) | 169 (63.1%) | 174 (65.2%) | 164 (61.2%) | Â | |
unknown | 155 (19.3%) | 63 (23.5%) | 44 (16.5%) | 48 (17.9%) | Â | |
PAM50 subtype | LumA | 393 (48.9%) | 125 (46.6%) | 132 (49.4%) | 136 (50.7%) | 0.008 |
LumB | 216 (26.9%) | 92 (34.3%) | 69 (25.8%) | 55 (20.5%) | Â | |
HER2 | 87 (10.8%) | 20 (7.5%) | 31 (11.6%) | 36 (13.4%) | Â | |
Basal | 51 (6.4%) | 20 (7.5%) | 14 (5.2%) | 17 (6.3%) | Â | |
Normal | 56 (7.0%) | 11 (4.1%) | 21 (7.9%) | 24 (9.0%) | Â |